Literature DB >> 32276687

Epinephrine in the Management of Anaphylaxis.

Julie C Brown1, Elinor Simons2, Susan A Rudders3.   

Abstract

Epinephrine is life-saving and the only first-line medication in the management of anaphylaxis. At therapeutic doses, it acts rapidly to reverse nearly all symptoms of anaphylaxis, and stabilize mast cells. The standard approved doses administered intramuscularly in the lateral thigh have a long track record for safe and effective use, but more information is needed on epinephrine pharmacokinetics and pharmacodynamics to ensure that current dosing strategies are optimal. Epinephrine should be administered promptly once anaphylaxis is suspected, to minimize morbidity and mortality. Providers on the front-line for managing patients with life-threatening allergic reactions need clear parameters and tools to guide the appropriate use of epinephrine, which take into account the potential evolution of symptoms and signs over time. All patients at risk for anaphylaxis should carry 2 epinephrine autoinjectors and be taught and able to demonstrate how to use them. Epinephrine autoinjectors need to be affordable, readily available, and easy for patients with allergies to carry and use. Furthermore, these devices should be available to meet the needs of all patients, from small infants through large or obese adults. The ideal means for storing and delivering epinephrine in prehospital and hospital environments warrants further study, to determine how to best balance efficiency, safety, and costs.
Copyright © 2020. Published by Elsevier Inc.

Entities:  

Keywords:  Anaphylaxis; Autoinjector; Auvi-Q; Benefit; Cost; Delivery; Dose; Emerade; EpiPen; Epinephrine; Generic; Length; Management; Needle; Pharmacokinetics; Teva

Mesh:

Substances:

Year:  2020        PMID: 32276687     DOI: 10.1016/j.jaip.2019.12.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol Pract


  5 in total

Review 1.  Approach to Perioperative Anaphylaxis in 2020: Updates in Diagnosis and Management.

Authors:  Jerry Kalangara; Kristine Vanijcharoenkarn; Grant C Lynde; Nichole McIntosh; Merin Kuruvilla
Journal:  Curr Allergy Asthma Rep       Date:  2021-01-06       Impact factor: 4.806

Review 2.  Emerging Therapies in Anaphylaxis: Alternatives to Intramuscular Administration of Epinephrine.

Authors:  Brittany Boswell; Susan A Rudders; Julie C Brown
Journal:  Curr Allergy Asthma Rep       Date:  2021-03-05       Impact factor: 4.806

3.  CSACI position statement: transition recommendations on existing epinephrine autoinjectors.

Authors:  Lucy Dong Xuan Li; Elissa M Abrams; Elana Lavine; Kyla Hildebrand; Douglas Paul Mack
Journal:  Allergy Asthma Clin Immunol       Date:  2021-12-13       Impact factor: 3.406

Review 4.  The 2020 update on anaphylaxis in paediatric population.

Authors:  Izabela Tarczoń; Ewa Cichocka-Jarosz; Anna Knapp; Przemko Kwinta
Journal:  Postepy Dermatol Alergol       Date:  2021-02-06       Impact factor: 1.837

5.  The Timely Administration of Epinephrine and Related Factors in Children with Anaphylaxis.

Authors:  Lily Myung-Jin Cha; Won Seok Lee; Man Yong Han; Kyung Suk Lee
Journal:  J Clin Med       Date:  2022-09-20       Impact factor: 4.964

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.